PAN Cancer trial

Chief Investigator: Professor Rebecca Fitzgerald, MRC Cancer Unit

Principal Investigators:
Dr Massimiliano di Pietro, gastric and oesophageal cancers
Miss Alexandra Colquhoun, bladder cancer
Mr Vincent Gnanapragasam, prostate cancer
Mr Grant Stewart, renal cancer
Dr Edmund Godfrey, pancreatic cancer
Miss Victoria Snowdon, liver cancer

Sponsor's coordinating Investigator: Dr Marc van der Schee

Funded by: Owlstone Medical Ltd (sponsors) and CRUK Cambridge Centre

The PAN-cancer study is a collaboration between the Cancer Research UK Cambridge Centre, Owlstone Medical Ltd and Cambridge University Hospitals NHS Foundation Trust. The study is evaluating whether Owlstone Medical’s Breath Biopsy® technology can differentiate between patients with and without different cancer types by comparing breath biomarkers in gastric, oesophageal, renal, prostate, bladder, liver and pancreatic cancer and healthy volunteers. This study is the first step in evaluating volatile organic compounds analysis as a test to improve early detection rates for cancer with future applicability to primary care.

The PAN-cancer study is a collaboration between the Cancer Research UK Cambridge Centre, Owlstone Medical Ltd (sponsors) and Cambridge University Hospitals NHS Foundation Trust to evaluate Owlstone Medical’s Breath Biopsy® technology.

Further information can be found here.